Menu
FM Ashkenazi meets with Cypriot FM Nikos Christodoulides

FM Ashkenazi meets with Cypriot FM …

FM Ashkenazi: Israel and ...

MFA hosts virtual conference on digital diplomacy during the corona crisis

MFA hosts virtual conference on dig…

Some 150 participants wil...

PM Netanyahu chairs Corona Cabinet meeting

PM Netanyahu chairs Corona Cabinet …

The goal of the policy is...

Israel marks Memorial Day for the fallen soldiers and victims of terrorism

Israel marks Memorial Day for the f…

Remembrance Day, Yom Hazi...

President Rivlin and FM Katz host reception for the diplomatic and consular corps in Israel

President Rivlin and FM Katz host r…

President Rivlin: Althoug...

Special Holy Fire ceremony held during the coronavirus outbreak

Special Holy Fire ceremony held dur…

The traditional Holy Fire...

PM Netanyahu addresses the ceremony marking Holocaust Martyrs' and Heroes' Remembrance Day

PM Netanyahu addresses the ceremony…

Prime Minister Benjamin N...

Holocaust Martyrs' and Heroes' Remembrance Day 20-21 April 2020

Holocaust Martyrs' and Heroes' Reme…

The official Opening Cere...

Briefing for foreign ambassadors on Coronavirus management and cooperation with the Palestinians

Briefing for foreign ambassadors on…

During the briefing, the ...

Yad L'Achim Opens Hotline for Assistance from Experienced Psychologists, Social Workers

Yad L'Achim Opens Hotline for Assis…

Confused? Under Pressure?...

Prev Next
A+ A A-
Booking.com

Safer radiation therapy

 

An Israeli company's biodegradable 'balloon' radically reduces the negative side effects of radiation in cancer treatment.

 

 

By Desmond Bentley
The main drawback of radiation therapy for cancer patients is that it harms healthy tissues surrounding a malignant tumor under radiation bombardment.
Now the Israeli company BioProtect has come up with a unique biodegradable "balloon" that physically separates cancerous and healthy tissues during radiation therapy for prostate cancer.
BioProtect's CEO, Amir Shiner, says the company's trademarked ProSpace represents a breakthrough in its field. "We're bringing a new product to the market," he says. "There's a clear clinical need for this product in view of the support by numerous publications for escalating radiation doses to prostate cancer patients undergoing radiation therapy. It makes the therapy far more effective."
In a multi-center, international study involving 26 prostate cancer patients, ProSpace was shown to significantly reduce the radiation reaching the rectal wall and consequent associated complications. It therefore allows for radiation at high doses without ill effects, meaning more efficient treatments with fewer treatment sessions at lower cost.
How does it work?
Made from biodegradable polymers, which have a proven safety record, the ProSpace device is filled with saline and implanted using the minimally invasive, well-established technique of transperineal insertion commonly used at outpatient centers.
The balloon remains inflated throughout the radiation therapy treatment. It then dissolves and reabsorbs into the body within three to six months, eliminating the need for removal. Patients involved in the trial reported that they felt no discomfort or pain from the implanted balloon, aside from mild and temporary discomfort at the access area at the perineum.
Because radiation therapy is a well-established, effective and widely accepted form of treatment for many types of cancer, it is expected that the BioProtect device can be used to implement safer and more effective radiation therapies for a variety of cancers.
"There's a strong need to have such a protection device," says Shiner, noting that BioProtect is not alone in this market. "There is one company that provides a gel product that is injected for the same need. Competition is always good - the feedback we've received from physicians is that they far prefer our product. It has a clear advantage in that it is reproducible. Due to its reproducible shape and size, and well-defined boundaries under a CT scan, it helps the doctor to administer the treatment effectively."
Europe first
In October 2010, ProSpace received the CE Mark, ensuring that it conforms to European regulatory requirements. BioProtect is now establishing a marketing network in Europe. "In April we started in Italy, and have now signed distribution agreements in five European countries," reports Shiner. "We're in the middle of a soft-launch process in those countries, and are negotiating to expand further in Europe, where we already have initial sales."
Last July, the ProSpace device received Israeli Health Ministry approval for marketing. In January, the company will launch a study utilizing its balloon for an innovative radiation therapy protocol at several medical centers in Israel.
In the United States, the company has already carried out a pilot study for the Food and Drug Administration and is now discussing with the FDA further clinical requirements to obtain clearance, says Shiner.
"We're a small company, based in Kfar Saba. Our R&D team and manufacturing are on site, while we are strongly focused on clinical activities, marketing and sales," he adds.
The company has already raised funds from three groups of investors: Xenia Venture Capital, which operates the technological incubator in Kiryat Gat where the company began as a startup; Virginia Life Science Investments, which invests in several Israeli healthcare companies; and the JumpStart NJ Angel Network. "We also have other private investors," notes Shiner. "Currently, we're working on more significant fundraising to take us to the next stage."

Last modified onMonday, 29 July 2013 11:14

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

back to top

Sections

Jewish Traditions

About Us

Community

Cooperations

Follow Us